ITI-214 Parkinson’s drug may be useful for heart failure patients
A drug currently in trials for Parkinson's disease has shown promise in treating heart failure, without the risk of dangerous side effects...
List view / Grid view
A drug currently in trials for Parkinson's disease has shown promise in treating heart failure, without the risk of dangerous side effects...
The onset of side effects of a common cancer treatment, anti-PD-1 therapy can be identified up to 3 years after treatment...
A novel drug based on capsaicin caused long-term weight loss and improved metabolic health in mice eating a high-fat diet...
The global clinical microbiology market is projected to reach USD 4.95bn by 2023 from USD 3.63bn in 2018, growing at a CAGR of 6.4% from 2018 to 2023.
Two companies will work closely together on future development, distribution, promotion, access, marketing and sales of Invokana (canagliflozin) for type 2 diabetes...
Novel regimen enables physicians to fully dose up to two months of Aristada treatment on day one...
A study shows low-dose aspirin may aid removal of harmful amyloid plaque in the brain...
The FDA has approved Epidiolex oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy...
A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival...
Pivot Pharmaceuticals Inc. is to begin human clinical trials of PVT-005, the pharmaceutical drug candidate for the treatment of HSDD...
PROSOLV® SMCC, silicified microcrystalline cellulose, is a unique combination of microcrystalline cellulose (MCC) and colloidal silicon dioxide (CSD)...
In this issue: the role of bioptherapeutics in curing a range of diseases, and is supercritical fluid chromatography applicable to achiral separations?
In this issue: Microfluidics technology in pharmaceutical research, drug manufacturing and development, and is supercritical fluid chromatography applicable to achiral separations?
A study has found a novel mechanism underlying stable, durable blood sugar control...